RESUMO
The epithelial-mesenchymal transition (EMT) is a phenomenon, in which epithelial cells acquire a mesenchymal cell phenotype. It is important during wound healing; however, chronic inflammation leads to excessive EMT and causes tissue barrier dysfunction with hyperplasia. EMT is induced by several cytokines, such as interleukin (IL)-4 and IL-13. Additionally, IL-4 and IL-13 are known to increase in atopic dermatitis (AD) characterized by intense itching and eczema. Therefore, we assumed that there was commonality between the respective EMT and AD phenotypes. Herein, we evaluated EMT marker expression in AD skin and demonstrated that EMT-maker Snai1 and Twist expression were increased in AD mice model and patients with AD. Moreover, the epithelial-marker keratin 5 and mesenchymal marker Vimentin were co-expressed in the skin epidermis of mice with AD, suggesting the existence of hybrid epithelial-mesenchymal (E/M) cells possessing both epithelial and mesenchymal characteristics. In fact, we found that ΔNp63a, a stabilizing factor for hybrid E/M cells, was upregulated in the skin epidermis of the AD model mouse. Interestingly, increased expression of EMT markers was observed even at a nonlesion site in a patient with AD without initial inflammation or scratching. Therefore, EMT-like phenomena may occur independently of wound healing in skin of patients with AD.
Assuntos
Dermatite Atópica , Humanos , Camundongos , Animais , Interleucina-13 , Epiderme , Transição Epitelial-Mesenquimal/genética , InflamaçãoRESUMO
BACKGROUND: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in Japanese infants. V114 contains all 13 serotypes in PCV13 plus additional serotypes 22F and 33F. METHODS: Healthy Japanese infants were randomized to receive three primary doses of V114 or PCV13 (dose 1 at 2-6 months of age; doses 2 and 3 ≥ 27 days after prior dose), plus a toddler dose at 12-15 months of age. Adverse events (AEs) were collected on Days 1-14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-dose 3, pre-dose 4, and 30 days post-dose 4. Primary objectives included non-inferiority of V114 to PCV13 for the 13 shared serotypes based on serotype-specific IgG response rates (IgG ≥ 0.35 µg/mL) and geometric mean concentration (GMC) ratios, and for serotypes 22F and 33F based on IgG response rates and compared with the lowest response of any serotype in the PCV13 group, at 30 days post-dose 3. RESULTS: Overall, 694 infants were randomized to V114 (n = 347) or PCV13 (n = 347). Proportions of participants with solicited and serious AEs were comparable between vaccination groups. V114 met non-inferiority criteria for all 13shared serotypes, based on difference in proportion of responders (lower bound of two-sided 95 % confidence interval [CI] > -10.0) and IgG GMC ratios (V114/PCV13, lower bound of two-sided 95 % CI > 0.5) at 30 days post-dose 3. The non-inferiority criterion based on IgG response rates was met for serotype 22F, but narrowly missed for serotype 33F (90.9 %, lower bound of two-sided 95 % CI -10.6). CONCLUSION: In Japanese infants, a four-dose series of V114 was generally well tolerated. Compared with PCV13, V114 provided non-inferior immune responses to the 13 shared serotypes and higher immune responses to serotype 22F and 33F post-primary series. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04384107; EudraCT 2019-003644-68.
Assuntos
Infecções Pneumocócicas , Humanos , Lactente , Vacinas Conjugadas , População do Leste Asiático , Anticorpos Antibacterianos , Imunoglobulina G , Vacinas Pneumocócicas , Imunogenicidade da VacinaRESUMO
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in adult invasive pneumococcal disease (IPD). This Phase I study assessed the safety, tolerability, and immunogenicity of V116 in Japanese adults. Participants ≥20 years of age were randomized to receive a single dose of V116 or 23-valent pneumococcal polysaccharide vaccine (PPSV23) at day 1. Outcomes were solicited injection-site and systemic adverse events (AEs) from day 1 to day 5, vaccine-related serious AEs from day 1 through day 30, and serotype-specific opsonophagocytic antibody (OPA) titers and immunoglobulin G (IgG) concentrations at day 30. Overall, 102 participants were randomized 1:1 to each group. Comparable proportions vaccinated with V116 and PPSV23 experienced ≥1 solicited injection-site AE and ≥1 solicited systemic AE. The most common injection-site AEs were injection-site pain (V116: 54.9%; PPSV23: 66.7%) and swelling (V116 and PPSV23: 13.7%), and the most common systemic AEs were myalgia (V116: 17.6%; PPSV23: 19.6%) and fatigue (V116: 13.7%; PPSV23: 9.8%). Solicited AEs were mostly mild and of ≤3 days duration. No vaccine-related serious AEs or deaths were reported. The OPA and IgG findings showed that the immunogenicity of V116 and PPSV23 were comparable for the 12 common serotypes and V116 was more immunogenic for the nine unique serotypes compared with PPSV23. V116 was well tolerated, with a safety profile similar to PPSV23, and induced functional antibodies against all 21 serotypes.
Assuntos
Imunogenicidade da Vacina , Infecções Pneumocócicas , Vacinas Pneumocócicas , Adulto , Humanos , População do Leste Asiático , Fadiga , Imunoglobulina G , Infecções Pneumocócicas/prevenção & controle , Vacinas Conjugadas/imunologia , Vacinas Pneumocócicas/imunologiaRESUMO
The safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), were assessed in a pivotal phase III trial conducted in healthy adults ≥50 years of age (NCT03950622, Japic-CTI 194845). We performed a subgroup analysis of 245 Japanese participants (all ≥65 years of age). The participants were randomized 1:1 to receive a single dose of V114 or 13-valent PCV (PCV13). Immune responses were evaluated at baseline and at 30 days post-vaccination. Non-serious and serious adverse events (AEs) were evaluated at 14 days and 6 months after vaccination, respectively. The proportions of participants experiencing solicited and serious AEs were comparable for both vaccines, and all solicited AEs were mild or moderate in severity. Geometric mean titers of serotype-specific opsonophagocytic activity (OPA) at 30 days post-vaccination were comparable between groups for all 13 shared serotypes and were higher with V114 for the unique serotypes 22F and 33F. The proportion of participants with a ≥4-fold increase in serotype-specific OPA responses from pre-vaccination to 30 days post-vaccination was higher for V114 than for PCV13 for serotypes 3, 22F, and 33F. V114 was well tolerated and immunogenic in Japanese adults ≥65 years of age, showing safety and immunogenicity profiles consistent with those seen in the overall study population.
Assuntos
Infecções Pneumocócicas , Streptococcus pneumoniae , Adulto , Humanos , Pessoa de Meia-Idade , Idoso , Vacinas Conjugadas/efeitos adversos , Japão , Anticorpos Antibacterianos , Vacinas Pneumocócicas/efeitos adversos , Sorogrupo , Infecções Pneumocócicas/prevenção & controleRESUMO
α-Lipoic acid is amphipathic with low molecular sulphur-containing fatty acid and has strong antioxidant effects. It has been used at the purposes of anti-ageing, treatment of diabetic neuropathy, and supplement as antioxidant. Though α-lipoic acid is normally administered in oral or injection, it has not been used in a topical use via skin because of its bad penetration. We developed the novel nanocapsule of α-lipoic acid, named α-lipoactive (nLA), to improve skin permeability. The nLA is constructed as micelles of α-lipoic acid mixed with the non-ionic surfactant, and its surface of the micelles was coated with inorganic metal salts. It is water soluble and has a diameter of approximately 8-15 nm. After nLA was applied to the murine skin, epidermal thickening was observed. It was confirmed that this effect is caused by α-lipoic acid molecule, but not by the raw material used for encapsulation. In in vivo experiments, it was found that nLA is very effective for improving UV-induced pigmentation and epidermal thickening. Our findings suggest that nanoencapsulation of α-lipoic acid is considerably effective for topical application.
Assuntos
Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Queratinócitos/efeitos dos fármacos , Nanocápsulas , Pigmentação da Pele/efeitos dos fármacos , Pele/efeitos dos fármacos , Ácido Tióctico/farmacologia , Administração Tópica , Animais , Antioxidantes/farmacologia , Cosméticos , Ácidos Graxos/química , Perfilação da Expressão Gênica , Cobaias , Queratinócitos/citologia , Masculino , Camundongos , Nanomedicina , Permeabilidade , Transdução de Sinais , Enxofre/química , Ácido Tióctico/química , Raios UltravioletaRESUMO
The anti-oxidant enzyme superoxide dismutase (SOD) has the potential for use as a therapeutic agent in the treatment of various diseases caused by reactive oxygen species. However, achieving this would be difficult without a suitable delivery system for SOD. We previously reported that PC-SOD, in which four molecules of a phosphatidylcholine (PC) derivative were covalently bound to each dimer of recombinant human CuZnSOD, was a high affinity for the cell membrane [14]. Here, we show that an octaarginine (R8) modified liposome equipped with PC-SOD (R8-LP (PC-SOD)) enhances its anti-oxidant effect. High-density R8-modified liposomes can stimulate macropinocytosis and are taken up efficiently by cells as demonstrated in a previous study [21]. Flow cytometry analyses showed that R8-LP (PC-SOD) was taken up by cells more efficiently than PC-SOD. Moreover, R8-LP (PC-SOD) liposomes were found to scavenge superoxide anions (O(2)(-)) very efficiently. These results suggest that the efficient cytosolic delivery of PC-SOD by R8-modified liposomes would enhance the anti-oxidant effects of PC-SOD.
Assuntos
Antioxidantes/administração & dosagem , Antioxidantes/metabolismo , Oligopeptídeos/química , Fosfatidilcolinas/administração & dosagem , Fosfatidilcolinas/metabolismo , Superóxido Dismutase/administração & dosagem , Superóxido Dismutase/metabolismo , Antioxidantes/química , Citometria de Fluxo , Células HeLa , Humanos , Lipossomos , Fosfatidilcolinas/química , Superóxido Dismutase/químicaRESUMO
The effect of Nano PGE(1) (nanoparticles containing prostaglandin E(1)) on spinal cord injury (SCI) was investigated in rat model. Nano PGE(1) significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE(1) was comparable with successive treatment of Lipo PGE(1), and was superior to single treatment of Lipo PGE(1). Distribution study revealed that Nano PGE(1) sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE(1) was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE(1) were detected in Nano PGE(1)-treated injured spinal cord as compared with that in normal ones. Nano PGE(1)-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE(1) had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE(1) to the injured spinal cord. The sustained release of PGE(1) would have increased HGF production, and both would have promoted cell survival and endogenous repair.
Assuntos
Alprostadil/farmacologia , Atividade Motora/efeitos dos fármacos , Neurônios Motores/efeitos dos fármacos , Músculo Esquelético/inervação , Nanopartículas , Traumatismos da Medula Espinal/tratamento farmacológico , Medula Espinal/efeitos dos fármacos , Alprostadil/química , Alprostadil/farmacocinética , Animais , Química Farmacêutica , Preparações de Ação Retardada , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Composição de Medicamentos , Feminino , Fator de Crescimento de Hepatócito/metabolismo , Membro Posterior , Neurônios Motores/metabolismo , Neurônios Motores/patologia , Proteína Básica da Mielina/metabolismo , Ratos , Ratos Sprague-Dawley , Recuperação de Função Fisiológica , Medula Espinal/metabolismo , Medula Espinal/patologia , Medula Espinal/fisiopatologia , Traumatismos da Medula Espinal/metabolismo , Traumatismos da Medula Espinal/patologia , Traumatismos da Medula Espinal/fisiopatologia , Fatores de Transcrição/metabolismoRESUMO
PURPOSE: We recently developed prostaglandin E(1) (PGE(1))-encapsulated nanoparticles, prepared with a poly(lactide) homopolymer (PLA, Mw = 17,500) and monomethoxy poly(ethyleneglycol)-PLA block copolymer (PEG-PLA) (NP-L20). In this study, we tested whether the accelerated blood clearance (ABC) phenomenon is observed with NP-L20 and other PEG-modified PLA-nanoparticles in rats. METHODS: The plasma levels of PGE(1) and anti-PEG IgM antibody were determined by EIA and ELISA, respectively. RESULTS: Second injections of NP-L20 were cleared much more rapidly from the circulation than first injections, showing that the ABC phenomenon was induced. This ABC phenomenon, and the accompanying induction of anti-PEG IgM antibody production, was optimal at a time interval of 7 days between the first and second injections. Compared to NP-L20, NP-L33s that were prepared with PLA (Mw = 28,100) and have a smaller particle size induced production of anti-PEG IgM antibody to a lesser extent. NP-L20 but not NP-L33s gave rise to the ABC phenomenon with a time interval of 14 days. NP-L33s showed a better sustained-release profile of PGE(1) than NP-L20. CONCLUSIONS: This study revealed that the ABC phenomenon is induced by PEG-modified PLA-nanoparticles. We consider that NP-L33s may be useful clinically for the sustained-release and targeted delivery of PGE(1).
Assuntos
Nanopartículas/administração & dosagem , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/farmacocinética , Animais , Tempo de Circulação Sanguínea/efeitos dos fármacos , Taxa de Depuração Metabólica/efeitos dos fármacos , Taxa de Depuração Metabólica/fisiologia , Tamanho da Partícula , Ratos , Ratos Wistar , Fatores de TempoRESUMO
PURPOSE: Prostaglandin E(1) (PGE(1)) is an effective treatment for peripheral vascular diseases. The encapsulation of PGE(1) in nanoparticles for its sustained-release would improve its therapeutic effect and quality of life (QOL) of patients. METHODS: In order to encapsulate PGE(1) in nanoparticles prepared with a poly(lactide) homopolymer (PLA) and monomethoxy poly(ethyleneglycol)-PLA block copolymer (PEG-PLA), we synthesized a series of PGE(1) phosphate derivatives and tested their efficacy. RESULTS: Among them, PGE(1) 2-(phosphonooxy)ethyl ester sodium salt (C2) showed the most efficient hydrolysis to yield PGE(1) in human serum. An in vitro platelet aggregation assay showed that C2 inhibited aggregation only after pre-incubation in serum, suggesting that C2 is a prodrug of PGE(1). In vivo, intravenous administration of C2 caused increase in cutaneous blood flow. In the presence of zinc ions, all of the synthesized PGE(1) phosphate derivatives could be encapsulated in PLA-nanoparticles. Use of L-PLA instead of D,L-PLA, and high molecular weight PLA resulted in a slower release of C2 from the nanoparticles. CONCLUSIONS: We consider that C2-encapsulated nanoparticles prepared with L-PLA and PEG-D,L-PLA have good sustained-release profile of PGE(1), which is useful clinically.
Assuntos
Alprostadil/administração & dosagem , Alprostadil/síntese química , Portadores de Fármacos/química , Nanopartículas/química , Fosfatos/química , Alprostadil/metabolismo , Alprostadil/farmacologia , Animais , Humanos , Hidrólise , Ácido Láctico/química , Tamanho da Partícula , Fosfatos/síntese química , Agregação Plaquetária/efeitos dos fármacos , Poliésteres , Polietilenoglicóis/química , Polímeros/química , Pró-Fármacos/metabolismo , Ratos , Ratos Wistar , Fluxo Sanguíneo Regional/efeitos dos fármacos , Soro/metabolismo , Pele/irrigação sanguínea , Zinco/químicaRESUMO
The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)carbamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), betaIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 microM) combined with BDNF (100 ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.
Assuntos
Benzoatos/farmacologia , Transtornos dos Movimentos/tratamento farmacológico , Transtornos dos Movimentos/fisiopatologia , Retinoides/farmacologia , Traumatismos da Medula Espinal/tratamento farmacológico , Traumatismos da Medula Espinal/fisiopatologia , Tetra-Hidronaftalenos/farmacologia , Animais , Biomarcadores , Western Blotting , Diferenciação Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Feminino , Membro Posterior/inervação , Membro Posterior/fisiologia , Humanos , Ceratolíticos/farmacologia , Locomoção/efeitos dos fármacos , Transtornos dos Movimentos/etiologia , Proteínas do Tecido Nervoso/biossíntese , Neurônios/efeitos dos fármacos , Neurônios/ultraestrutura , Ratos , Ratos Sprague-Dawley , Traumatismos da Medula Espinal/complicações , Tretinoína/farmacologiaRESUMO
Ulcerative colitis (UC) involves intestinal mucosal damage induced by reactive oxygen species (ROS), in particular, superoxide anion. Superoxide dismutase (SOD) catalyzes dismutation of superoxide anion to hydrogen peroxide, which is subsequently detoxified by catalase. Lecithinized SOD (PC-SOD) is a new modified form of SOD that has overcome previous clinical limitations of SOD. In this study, we examined the action of PC-SOD using an animal model of UC, dextran sulfate sodium (DSS)-induced colitis. DSS-induced colitis was ameliorated by daily intravenous administration of PC-SOD. Unmodified SOD produced a similar effect but only at more than 30 times the concentration of PC-SOD. In vivo electron spin resonance analysis confirmed that the increase in the colonic level of ROS associated with development of colitis was suppressed by PC-SOD administration. The dose-response profile of PC-SOD was bell-shaped, but simultaneous administration of catalase restored the ameliorative effect at high doses of PC-SOD. Accumulation of hydrogen peroxide was observed with the administration of high doses of PC-SOD, an effect that was suppressed by the simultaneous administration of catalase. We also found that either a weekly intravenous administration or daily oral administration of PC-SOD conferred protection. These results suggest that PC-SOD achieves its ameliorative effect against colitis through decreasing the colonic level of ROS and that its ineffectiveness at higher doses is because of the accumulation of hydrogen peroxide. Furthermore, we consider that intermittent or oral administration of PC-SOD can be applied clinically to improve the quality of life of UC patients.
Assuntos
Colite Ulcerativa/tratamento farmacológico , Fosfatidilcolinas/uso terapêutico , Superóxido Dismutase/uso terapêutico , Animais , Catalase/uso terapêutico , Colo/anatomia & histologia , Colo/efeitos dos fármacos , Colo/enzimologia , Primers do DNA , DNA Complementar/genética , Humanos , Imuno-Histoquímica , Interleucina-1/genética , Interleucina-23/genética , Interleucina-6/genética , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Mucosa Intestinal/fisiopatologia , Camundongos , Neutrófilos/fisiologia , Peroxidase/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
Transplantation of mature adipocyte-derived cells (dedifferentiated fat cells) led to marked functional recovery from spinal cord injury (SCI)-induced motor dysfunction in rats. When mature adipocytes were isolated from rat adipose tissue and grown in ceiling culture, transformation into fibroblast-like cells without lipid droplets occurred. These fibroblast-like cells, termed dedifferentiated fat cells (DFAT), could proliferate and could also differentiate back into adipocytes. DFAT expressed neural markers such as nestin, betaIII tubulin, and GFAP. Allografting of DFAT into SCI-induced rats led to significant recovery from hindlimb dysfunction. Grafted cells were detected at the injection site, and some of these cells expressed betaIII tubulin. DFAT expressed neurotrophic factors such as BDNF and GDNF prior to transplantation, and grafted cells were also positive for these factors. Therefore, these neurotrophic factors derived from grafted DFAT might have contributed to the promotion of functional recovery. These findings also suggest that mature adipocytes could become a new source for cell replacement therapy to treat central nervous system disorders.
Assuntos
Adipócitos/transplante , Transtornos dos Movimentos/terapia , Recuperação de Função Fisiológica/fisiologia , Traumatismos da Medula Espinal/terapia , Transplante de Células-Tronco , Células-Tronco/metabolismo , Animais , Biomarcadores/análise , Biomarcadores/metabolismo , Diferenciação Celular/fisiologia , Células Cultivadas , Modelos Animais de Doenças , Feminino , Fibroblastos/citologia , Fibroblastos/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Proteínas de Filamentos Intermediários/metabolismo , Masculino , Transtornos dos Movimentos/fisiopatologia , Fatores de Crescimento Neural/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Nestina , Organelas/metabolismo , Organelas/ultraestrutura , Ratos , Ratos Sprague-Dawley , Traumatismos da Medula Espinal/fisiopatologia , Células-Tronco/citologia , Resultado do Tratamento , Tubulina (Proteína)/metabolismoRESUMO
Gemcitabine(GEM)is the standard therapy for advanced pancreatic cancer. GEM-oxaliplatin (GEMOX) combination treatment has been reported to be superior to GEM alone in terms of clinical progression-free survival, but it is not the therapy of choice for pancreatic cancer. We report a case of advanced mucinous cystic neoplasm (MCN) of the pancreas with multiple hepatic metastases in a 39-year-old female. She was treated with 16 courses of GEMOX (GEM 1,500 mg/day at a rate of 10 mg/m2/min on the first day and oxaliplatin 150 mg/day at 100 mg/m2 on the second day, every 3 weeks). The pharmacist helped her to avoid severe side effects. When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment. No recurrence has been observed 22 months postoperatively. GEMOX might be effective for the treatment of MCN of the pancreas.
Assuntos
Cistadenoma Mucinoso/tratamento farmacológico , Cistadenoma Mucinoso/patologia , Desoxicitidina/análogos & derivados , Neoplasias Hepáticas/tratamento farmacológico , Compostos Organoplatínicos/uso terapêutico , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/patologia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cistadenoma Mucinoso/cirurgia , Desoxicitidina/uso terapêutico , Feminino , Humanos , Neoplasias Hepáticas/secundário , Imageamento por Ressonância Magnética , Metástase Neoplásica/diagnóstico por imagem , Metástase Neoplásica/tratamento farmacológico , Metástase Neoplásica/patologia , Estadiamento de Neoplasias , Oxaliplatina , Neoplasias Pancreáticas/cirurgia , Radiografia , GencitabinaRESUMO
The success of targeting systems to alveolar macrophages critically depends on internalization into these cells for pharmacological intervention. Direct respiratory delivery via inhalation of mannose modified liposomal carriers to alveolar macrophages is of great interest. To evaluate the targeting efficiency to alveolar macrophages by intratracheal administration of mannosylated liposomes (Man-liposomes), Man-liposomes with various ratio of mannosylated cholesterol derivatives, cholesten-5-yloxy-N-(4-((1-imino-2-D-thiomannosylethyl)amino)alkyl)formamide (Man-C4-Chol) as mannose receptor ligand were investigated with regard to their in vitro uptake in primary cultured alveolar macrophages and in vivo intratracheal administration in rats. The in vitro uptake of Man-liposomes took place in a concentration-dependent manner. The internalization of Man-liposomes with 7.5% (Man-7.5-liposomes) and 5.0% (Man-5.0-liposomes) Man-C4-Chol was considerably higher than that of Man-liposomes with 2.5% of Man-C4-Chol (Man-2.5-liposomes) and Bare-liposomes and significantly inhibited by an excess of mannan, suggesting mannose receptor-mediated endocytosis. After intratracheal administration of Man-7.5 and Man-5.0-liposomes in rats, a significantly high internalization and selective targeting to alveolar macrophages was observed. The enhanced cellular uptake in alveolar macrophages related to the mannose density of Man-liposomes was also confirmed both in vitro and in vivo confocal microscopy studies. These results demonstrate the efficient targeting to alveolar macrophages by the intratracheally administered Man-liposomes via mannose receptor-mediated endocytosis.
Assuntos
Sistemas de Liberação de Medicamentos , Lipossomos/administração & dosagem , Macrófagos Alveolares/metabolismo , Manose/administração & dosagem , Animais , Células Cultivadas , Colestenos/administração & dosagem , Colestenos/química , Colestenos/metabolismo , Colesterol/administração & dosagem , Colesterol/química , Colesterol/metabolismo , Vias de Administração de Medicamentos , Células Epiteliais/metabolismo , Lectinas Tipo C/metabolismo , Lipossomos/química , Lipossomos/metabolismo , Masculino , Mananas/farmacologia , Manose/química , Manose/metabolismo , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Microscopia Confocal , Fosfatidilcolinas/administração & dosagem , Fosfatidilcolinas/química , Fosfatidilcolinas/metabolismo , Surfactantes Pulmonares/farmacologia , Ratos , Ratos Wistar , Receptores de Superfície Celular/metabolismoRESUMO
The comparison study was performed with 3 kinds of Lipo PGE(1) (5 microg/ml) preparations (Formulation A, B, and C), which are now used in clinical. Under alkali condition, Lipo PGE(1) (5 microg/ml) preparations in combination with physiological solution containing calcium ion were susceptible to stop dropping because of the formation of aggregates. There was a difference of feasibility to form aggregates among these preparations. The percentage of PGE(1) in the LM (lipid microspheres) was 68.8% (Formulation A) when determined by filtration with the pore size of 0.1 microm, and the respective value (%) of Formulation B and Formulation C was 43.0% and 13.9%. This indicates that the latter formulations were significantly susceptible to leak from the LM. PGE(1) can induce an extensive irritation. The potency of irritation was the most in Formulation C. This seems similar with the result of LM retention of PGE(1). PGE(1) increased the blood flow. Formulation A reached the peak by 2.27 fold, which was significantly higher than Formulation C and PGE(1) alone (PGE(1)-cyclodextrin, PGE(1)-CD). The peak was also significantly higher in Formulation B than that of PGE(1)-CD. The AUC value of blood flow rate showed a significant increase in Formulation A and Formulation B as compared to that of PGE(1)-CD. Drug retention in the LM can be a determinant factor for drug distribution and pharmacological effect. This study indicates that there can be some differences among Lipo PGE(1) preparations, which have the same drug dose.
Assuntos
Alprostadil , Alprostadil/administração & dosagem , Alprostadil/efeitos adversos , Alprostadil/farmacologia , Animais , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Composição de Medicamentos , Sistemas de Liberação de Medicamentos , Irritantes , Masculino , Microesferas , Ratos , Ratos Wistar , Pele/efeitos dos fármacosRESUMO
The present study investigated whether plasma could be useful as a scaffold for cell transplantation in rats with spinal cord injury (SCI). Transplantation of cells with plasma promoted the recovery of SCI-induced motor dysfunction. Immunohistochemical analysis revealed that the grafted cells had differentiated into the neural lineage. When dissociated neural precursor cells were cultured with plasma, extensive neurite outgrowth was observed along with increased expression of p35 and NF68. Neural markers were also expressed by the cultured cells. Culture with plasma reduced thymidine incorporation, but promoted cell growth and increased the RNA contents. These findings suggest that the cells underwent differentiation into neurons in the presence of plasma. In conclusion, plasma could be a promising scaffold for cell transplantation therapy.
Assuntos
Células-Tronco Embrionárias/transplante , Regeneração Nervosa , Neurônios/citologia , Plasma/fisiologia , Traumatismos da Medula Espinal/terapia , Animais , Biomarcadores/metabolismo , Diferenciação Celular , Linhagem da Célula , Proliferação de Células , Sobrevivência Celular , Células-Tronco Embrionárias/fisiologia , Imuno-Histoquímica , Fatores de Crescimento Neural/metabolismo , Neurônios/metabolismo , RNA/metabolismo , Ratos , Traumatismos da Medula Espinal/patologiaRESUMO
BACKGROUND: This study evaluates the pharmacokinetic and pharmacodynamic effects of a transdermally delivered insulin using novel CaCO(3)-nanoparticles in normal mice and those with diabetes. METHODS: CaCO3-nanoparticles encapsulating insulin (nanoinsulin) were transdermally applied to the back skin of normal ddY mice and dB/dB and kkAy mice with diabetes after fasting for 1 h. Serum insulin levels of ddY mice were analyzed by enzyme immunoassay, and blood glucose of normal mice and those with diabetes was monitored. RESULTS: Maximum serum insulin was 67.1 +/- 25.9 microIU/mL at 4 h with 200 microg of transdermal nanoinsulin in ddY mice, whereas that after subcutaneous injection of 3 microg of monomer insulin was 462 +/- 20.9 microIU/mL at 20 min. Transdermal nanoinsulin decreased glucose levels in a dose-dependent manner. A maximum decrease in blood glucose of 48.3 +/- 3.9% (ddY), 32.5 +/- 9.8% (dB/dB), and 26.2 +/- 7.6% (kkAy) after 6 h was observed with 200 microg of transdermal nanoinsulin, compared with 64.1+/-1.0% (ddY), 57.9 +/-3.4% (dB/dB), and 24.1 +/- 6.7% (kkAy) after 1 h with 3 microg of subcutaneous monomer insulin. Insulin bioavailability until 6 h with transdermal nanoinsulin in ddY mice was 0.9% based on serum insulin level and 2.0% on pharmacodynamic blood glucose-lowering effects. CONCLUSIONS: This CaCO(3)-nanoparticle system successfully delivered insulin transdermally, as evidenced by a significant sustained decrease in blood glucose in normal mice and those with diabetes. These results support the feasibility of developing transdermal nanoinsulin for human applications.
Assuntos
Carbonato de Cálcio/administração & dosagem , Insulina/administração & dosagem , Insulina/sangue , Administração Cutânea , Animais , Insulina/farmacocinética , Camundongos , Camundongos Endogâmicos , Nanoestruturas , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/sangueRESUMO
The effectiveness of two inducible nitric oxide synthase (iNOS) inhibitors on allergic airway inflammation was investigated under different administration schedules. Rats sensitized to ovalbumin (OVA) were exposed to OVA for 3 consecutive days. Both iNOS inhibitors showed markedly different effects between two pretreatment schedules: pretreatment before each of three OVA exposures S1 and before the third exposure alone S2. S1 pretreatment resulted in higher pulmonary resistance than triple OVA alone. This potentiation was associated with increased eosinophil infiltration and malondialdehyde levels in the lungs, which were suppressed by superoxide dismutases (SODs) but not by methylprednisolone. However, the S2 administration of both iNOS inhibitors completely suppressed the airway response. Administration by schedule S1 completely suppressed plasma nitrite and nitrate levels, but that by S2 caused only a slight suppression. The triple OVA exposures resulted in the upregulation of iNOS in alveolar macrophages and arginase activity, Mn- and Cu/Zn-SOD expression, and nitrotyrosine and lipid peroxide deposition in the airway. However, inhibitors administered by schedule S1 suppressed this upregulation, but further potentiated nitrotyrosine, which in turn was inhibited by SOD. Although iNOS inhibitors may be beneficial for asthma, repeated administration may be detrimental because of extensive reduction of NO and downregulation of SOD.
Assuntos
Amidinas/uso terapêutico , Asma/tratamento farmacológico , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Guanidinas/uso terapêutico , Óxido Nítrico Sintase Tipo II/antagonistas & inibidores , Amidinas/farmacologia , Animais , Arginase/metabolismo , Asma/induzido quimicamente , Líquido da Lavagem Broncoalveolar/citologia , Regulação para Baixo , Sinergismo Farmacológico , Guanidinas/administração & dosagem , Compostos Heterocíclicos com 2 Anéis/farmacologia , Compostos Heterocíclicos com 2 Anéis/uso terapêutico , Peróxidos Lipídicos/metabolismo , Pulmão/enzimologia , Pulmão/patologia , Pulmão/fisiologia , Masculino , Ovalbumina/imunologia , Ratos , Ratos Endogâmicos BN , Superóxido Dismutase/biossínteseRESUMO
All-trans Retinoic Acid (atRA), is known as a member of retinoid, and the atRA nano-particle with coated by CaCO3 (nanoegg -atRA), was recently developed as a new drug delivery system (DDS). This nanoparticles stimulated insulin secretion from islets in a glucose-dependent manner at streptozotocin (STZ)-induced diabetes. The stains on pancreas of Wistar rat at STZ induced diabetes, which was subcutaneous administered nanoegg -atRA 6 mg/head/week for 141 days, showed not only the expression of PDX-1 but also the presence of beta cell in islet of Langerhans. Furthermore, the increase of insulin concentration in plasma was also observed. Our data indicate that nanoegg -atRA might contribute to the regeneration of beta cells in vivo, and provide useful information for future therapy of diabetes mellitus.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Insulina/metabolismo , Ilhotas Pancreáticas/efeitos dos fármacos , Nanoestruturas , Tretinoína/administração & dosagem , Animais , Secreção de Insulina , Ilhotas Pancreáticas/citologia , Masculino , Ratos , Ratos WistarRESUMO
PC-SOD (lecithinized superoxide dismutase) is a derivative of human Cu, Zn-SOD conjugated with 4 molecules of lecithin, yet having the enzyme activity of scavenging superoxide anion (O2-). Intravenous administration of PC-SOD promoted the recovery from spinal cord injury (SCI)-induced motor dysfunction in a dose-dependent manner in rat model, when evaluated by BBB (Basso Beattie Bresnahan) score. Even when given at 24 h after SCI, PC-SOD (1 mg/kg) significantly improved motor dysfunction. Distribution study demonstrated that PC-SOD gradually accumulated to the injured site. Enzyme-linked immunoassay revealed that PC-SOD prevented quantitative loss of neurons, astrocytes, and oligodendrocytes. PC-SOD inhibited SCI-induced oxidative stress, such as the decrease of free sulfhydryl residue, acetylcholine esterase activity, and the increase of lipid peroxidation. PC-SOD increased the production of neuroprotective factors. HIF-1alpha gene expression increased following SCI, and PC-SOD further increased it. In conclusion, PC-SOD gradually accumulated and retained at the damaged site to scavenge excessive O2-, and suppressed neuronal death through reducing oxidative stress, increasing neuroprotective factor production and HIF-1alpha gene expression.